Discover 7 college majors designed to help students thrive in an AI-driven economy—build skills in leadership, innovation, ...

XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the ...

AI has been a buzzword in the pharmaceutical industry for almost a decade, with countless headlines promising to ...

Drug discovery has traditionally been slow, expensive and prone to failure, but AI and machine learning are set to change all ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

Expanded alliance combines Lisata’s drug development expertise with GATC’s AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug ...

A deal between Shenzhen-based XTalPi and US firm DoveTree shows Chinese biotech AI capabilities are gaining recognition.

Symbiotic.blue, a biotech looking to build an AI-driven drug discovery platform, has begun a pre-seed funding round.

Given the variability between labs and the unique nature of R&D work, custom, niche AI tools are going to become much more ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

Despite longstanding reliance on sputum smear microscopy, culture methods, and chest X-rays, conventional TB diagnostics ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...